Mucoadhesive Polymer Tangeretin Loaded Chitosan Nanoparticles to Combat the Resistance of Mycobacterium Tuberculosis

Present methods of care the recommended course of treatment for Mycobacterium tuberculosis (MTB) resistance involves taking first-line medications orally for 4–6 months. Nonetheless, serious negative consequences result from this strategy. For the purpose of treating MTB resistance, chitosan nanoparticles (CSNPs) have been the subject of extensive research into controlled release drug delivery systems. A chitosan nanoparticle encapsulated O-polymethoxylated flavone called tangeretin was used in this investigation. Several approaches were used to characterize this nanoparticle (TN-CSNPs) that were successfully obtained. Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., Staphylococcus aureus, Klebsiella pneumoniae, and TB resistant strains were tested for antimicrobial activity in both planktonic and biofilm development phases. Utilizing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test in treated cells, the bioavailability of the nanoparticles has been evaluated. The TN-CSNPs demonstrated enhanced inhibitory effectiveness against both planktonic and adhering MTB strains, as well as resistant strains compared to chitosan alone treated groups. Additionally, the nanoparticles that were tested were found to be biocompatible with MRC-5 fibroblast cells. This suggests that they could be used to create novel therapeutic agents that are effective against MTB and other multidrug-resistant infections.